Chief Development Officer · Immunome Inc. (IMNM)

Dennis Giesing

FY2021 is the first fiscal year CompBrief holds for Dennis Giesing as a named executive officer of Immunome; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$3,499,917

Salary $306,971Stock awards $0Bonus $50,000

1st of 3 named executive officers at Immunome by FY2021 total.

3 named officers on file for Immunome, FY2021

Dennis Giesing’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunome’s whole pay program stands against its peers

  • Immunome’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Dennis Giesing’s full pay file as a PDF — free

More than this page: up to 10 years of Dennis’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Dennis Giesing compensation by year

Immunome Summary Compensation Table · the one fiscal year held
In US dollars, as Immunome reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$306,971
Bonus$50,000
Stock awards$0
Option awards$3,055,236
Non-equity incentive$84,318
Pension and deferred compensation$0
All other$3,392
Total$3,499,917

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunome Inc. DEF 14A filed April 29, 2022, accession 0001104659-22-053513, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunome Inc. filed document, accession 0001104659-22-053513. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option2,813—$11.38
Option16,609—$20.92
Option125,000—$31.83

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunome Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2021 proxy (filed April 29, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-06-08Grant or award derivative—50,000$0.0050,000

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Immunome’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Dennis Giesing · this pageChief Development Officer$3,499,917
Corleen RocheChief Financial Officer$3,096,344
Purnanand SarmaPresident, Chief Executive Officer and Director$2,111,914

The full Immunome compensation record

free company brief

This page is one person within Immunome's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunome's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Dennis Giesing's compensation dossier · One-time report. No refunds.